Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: Results from the DEpression in Patients with Coronary ARtery Disease (DECARD) trial

Journal of Cardiovascular Pharmacology

Volumn 60, Issue 4, 2012, Pages 397-405

  Hanash, Jamal A ^a   Hansen, Baiba H ^b   Hansen, Jørgen F ^c   Nielsen, Olav W ^c   Rasmussen, Alice ^a   Birket Smith, Morten ^b  

^a FREDERIKSBERG HOSPITAL   (Denmark)

^b Psychiatric Centre Bispebjerg   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

acute coronary syndrome; cardiovascular; escitalopram; safety

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ESCITALOPRAM; PLACEBO;

ACUTE CORONARY SYNDROME; AGED; ANORGASMIA; ARTICLE; ATRIOVENTRICULAR BLOCK; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; DEATH; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DREAM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EJACULATION DISORDER; ELECTROCARDIOGRAM; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART VENTRICLE ARRHYTHMIA; HUMAN; INTRAVENTRICULAR CONDUCTION DEFECT; LASSITUDE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT DISEASE; RESTLESSNESS; SEDATION; SIDE EFFECT; SLEEP; SOMNOLENCE; ST SEGMENT DEPRESSION; SWEATING; TENSION; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ACUTE CORONARY SYNDROME; AGED; CARDIOVASCULAR DISEASES; CITALOPRAM; DEPRESSION; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84867744245     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182677041     Document Type: Article

References (49)

1. Swenson JR, Doucette S, Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Can J Psychiatry. 2006;51:923-929.
2. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104:1894-1898.
3. Schlienger RG, Fischer LM, Jick H, et al. Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. Drug Saf. 2004;27:1157-1165.
4. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003;108:32-36.
5. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med. 2000;108:2-8.
6. Meier CR, Schlienger RG, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br J Clin Pharmacol. 2001;52:179-184.
7. Tata LJ, West J, Smith C, et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart. 2005;91:465-471.
8. Ziegelstein RC, Meuchel J, Kim TJ, et al. Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes. Am J Med. 2007;120:525-530.
9. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288:701-709.
10. Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62:792-798.
11. Rasmussen A, Lunde M, Poulsen DL, et al. A double-blind, placebocontrolled study of sertraline in the prevention of depression in stroke patients. Psychosomatics. 2003;44:216-221.
12. Hansen BH, Hanash JA, Rasmussen A, et al. Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of depression in acute coronary syndrome (DECARD). Trials. 2009;10:20.
13. Hansen BH, Hanash JA, Rasmussen A, et al. Effects of escitalopram in prevention of depression in patients with acute coronary syndrome (DECARD). J Psychosom Res. 2012;72:11-16.
14. Blazer DG. Self-efficacy and depression in late life: a primary prevention proposal. Aging Ment Health. 2002;6:315-324.
15. Alexopoulos GS. New concepts for prevention and treatment of late-life depression. Am J Psychiatry. 2001;158:835-838.
16. Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959-969.
17. WHO Collaborating Centre for Research and Training in Mental Health. Schedules for Clinical Assessment in Neuropsychiatry. Version 2.1. Aarhus, Denmark: WHO SCAN Advisory Committee; 2000:46-175.
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
19. Kearns NP, Cruickshank CA, McGuigan KJ, et al. A comparison of depression rating scales. Br J Psychiatry. 1982;141:45-49.
20. Scales for assessment of diagnosis and severity of mental disorders. Acta Psychiatr Scand Suppl. 1993;372:3-83.
21. Sajadieh A, Nielsen OW, Rasmussen V, et al. Ventricular arrhythmias and risk of death and acute myocardial infarction in apparently healthy subjects of age .or=55 years. Am J Cardiol. 2006;97:1351-1357.
22. Fei L, Malik M. Prediction of life-threatening arrhythmias: multifactorial risk stratification following acute myocardial infarction. Int J Angiol. 1997;6:241-253.
23. Vaage-Nilsen M, Rasmussen V, Sorum C, et al. ST-segment deviation during 24-hour ambulatory electrocardiographic monitoring and exercise stress test in healthy male subjects 51 to 75 years of age: the Copenhagen City Heart Study. Am Heart J. 1999;137:1070-1074.
24. Rose GA, Blackburn H. Cardiovascular survey methods. Monogr Ser World Health Organ. 1968;56:1-188.
25. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-367.
26. Berning J, Rokkedal NJ, Launbjerg J, et al. Rapid estimation of left ventricular ejection fraction in acute myocardial infarction by echocardiographic wall motion analysis. Cardiology. 1992;80:257-266.
27. Sanderson JE, Fraser AG. Systolic dysfunction in heart failure with a normal ejection fraction: echo-Doppler measurements. Prog Cardiovasc Dis. 2006;49:196-206.
28. Nagueh SF, Middleton KJ, Kopelen HA, et al. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol. 1997;30:1527-1533.
29. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
30. Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guideline for Industry-Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. FDA Center for Drug Evaluation and Research; 2007.
31. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf. 1999;20:277-287.
32. Spigset O, Hedenmalm K. Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions. Pharmacotherapy. 1997;17:348-352.
33. Fabian TJ, Amico JA, Kroboth PD, et al. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study. Arch Intern Med. 2004; 164:327-332.
34. Lara N, Baker GB, Archer SL, et al. Increased cholesterol levels during paroxetine administration in healthy men. J Clin Psychiatry. 2003;64: 1455-1459.
35. Hall WD. How have the SSRI antidepressants affected suicide risk? Lancet. 2006;367:1959-1962.
36. Koponen H, Lepola U, Leinonen E, et al. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiatr Scand. 1997;96:343-346.
37. Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet. 2007;46:281-290.
38. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373:746-758.
39. Feinstein RE, Blumenfield M, Orlowski B, et al. A national survey of cardiovascular physicians' beliefs and clinical care practices when diagnosing and treating depression in patients with cardiovascular disease. Cardiol Rev. 2006;14:164-169.
40. Lesperance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. 2007;297: 367-379.
41. Robinson RG, Jorge RE, Moser DJ, et al. Escitalopram and problemsolving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA. 2008;299:2391-2400.
42. Bush DE, Ziegelstein RC, Patel UV, et al. Post-myocardial Infarction Depression. Evidence Report/Technology Assessment No. 123. AHRQ Publication Number 05-E018-1. Rockville, MD: Agency for Healthcare Research and Quality; 2005.
43. Jorge RE, Robinson RG, Arndt S, et al. Mortality and poststroke depression: a placebo-controlled trial of antidepressants. Am J Psychiatry. 2003;160:1823-1829.
44. Khan A, Schwartz K, Redding N, et al. Psychiatric diagnosis and clinical trial completion rates: analysis of the FDA SBA reports. Neuropsychopharmacology. 2007;32:2422-2430.
45. Lavori P. Statistical issues: sample size and dropout. Psychopharmacol Ser. 1990;8:91-104.
46. Aromaa E, Tolvanen A, Tuulari J, et al. Personal stigma and use of mental health services among people with depression in a general population in Finland. BMC Psychiatry. 2011;11:52.
47. Carney RM, Freedland KE, Sheline YI, et al. Depression and coronary heart disease: a review for cardiologists. Clin Cardiol. 1997;20:196-200.
48. Whitehead DL, Strike P, Perkins-Porras L, et al. Frequency of distress and fear of dying during acute coronary syndromes and consequences for adaptation. Am J Cardiol. 2005;96:1512-1516.
49. Committee on Prevention of Mental Disorders. Division of biobehavioral sciences and mental disorders. In: Mrazek P, Haghfelt R, eds. Reducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research. Washington, DC: National Academy Press; 1994.